Dr. Andrew A. Muskovitz
Claim this profileWilliam Beaumont Hospital-Royal Oak
Studies Cancer
Studies Colorectal Cancer
8 reported clinical trials
19 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
BRCA1 positive
2Colorectal Cancer
Stage III
Stage IV
MLH1 positive
Affiliated Hospitals
Clinical Trials Andrew A. Muskovitz is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Atezolizumab + Chemotherapy
for Neuroendocrine Carcinoma
This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.
Recruiting1 award Phase 2 & 310 criteria
More about Andrew A. Muskovitz
Clinical Trial Related3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Andrew A. Muskovitz has experience with
- Atezolizumab
- Leucovorin Calcium, Fluorouracil, Oxaliplatin
- Bevacizumab
- Osimertinib
- Cisplatin
- Carboplatin
Breakdown of trials Andrew A. Muskovitz has run
Cancer
Colorectal Cancer
Colon Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew A. Muskovitz specialize in?
Andrew A. Muskovitz focuses on Cancer and Colorectal Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Andrew A. Muskovitz currently recruiting for clinical trials?
Yes, Andrew A. Muskovitz is currently recruiting for 5 clinical trials in Royal Oak Michigan. If you're interested in participating, you should apply.
Are there any treatments that Andrew A. Muskovitz has studied deeply?
Yes, Andrew A. Muskovitz has studied treatments such as Atezolizumab, Leucovorin Calcium, Fluorouracil, Oxaliplatin, Bevacizumab.
What is the best way to schedule an appointment with Andrew A. Muskovitz?
Apply for one of the trials that Andrew A. Muskovitz is conducting.
What is the office address of Andrew A. Muskovitz?
The office of Andrew A. Muskovitz is located at: William Beaumont Hospital-Royal Oak, Royal Oak, Michigan 48073 United States. This is the address for their practice at the William Beaumont Hospital-Royal Oak.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.